Anidulafungin

Generic Name: Anidulafungin

Brand Names: Ecalta, Eraxis

Drug Type: Small Molecule

Chemical Formula: C_₅₈H_₇₃N_₇O_₁₇

CAS Number: 166663-25-8

Unique Ingredient Identifier: 9HLM53094I

Background: Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.

Indication: 用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。

Associated Conditions: Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis

Associated Therapies: -

Clinical Trials

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Phase 3

Terminated

Conditions: Invasive Aspergillosis

Interventions: Drug: Azole
Drug: Anidulafungin

First Posted Date: 2021-05-06

Last Posted Date: 2024-05-07

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 66

Registration Number: NCT04876716

Locations: 🇧🇪
UZ Ghent, Ghent, Belgium
🇧🇪
UZ Leuven, Leuven, Belgium
🇳🇱
Erasmus Medical Center (EMC), Rotterdam, Zuid Holland, Netherlands

and more 1 locations

Negative Beta Glucan in ICU Patients

Phase 4

Completed

Conditions: Candidemia

Interventions: Drug: Anidulafungin

First Posted Date: 2012-11-27

Last Posted Date: 2019-07-08

Lead Sponsor: Universidade Federal do Rio de Janeiro

Target Recruit Count: 85

Registration Number: NCT01734525

Locations: 🇧🇷
Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Effect of Weight and/or Obesity on Anidulafungin Drug Concentrations

Phase 4

Completed

Conditions: Obesity
Mycoses

Interventions: Drug: Anidulafungin

First Posted Date: 2011-03-03

Last Posted Date: 2019-01-09

Lead Sponsor: Texas Tech University Health Sciences Center

Target Recruit Count: 20

Registration Number: NCT01307930

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

Phase 4

Completed

Conditions: Liver Disease
Fungal Infection

Interventions: Drug: Anidulafungin
Drug: Liposomal amphotericin B

First Posted Date: 2011-02-24

Last Posted Date: 2014-05-30

Lead Sponsor: Fundacion SEIMC-GESIDA

Target Recruit Count: 61

Registration Number: NCT01303549

Locations: 🇪🇸
Hospital de Bellvitge, Barcelona, Spain
🇪🇸
Hospital Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clinic i Provincial, Barcelona, Spain

and more 9 locations

Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom

Completed

Conditions: Candidiasis

Interventions: Drug: anidulafungin

First Posted Date: 2010-09-15

Last Posted Date: 2014-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT01202253

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Phase 3

Withdrawn

Conditions: Aspergillosis
Neuroaspergillosis
Invasive Pulmonary Aspergillosis

Interventions: Drug: Voriconazole
Drug: Anidulafungin

First Posted Date: 2010-08-25

Last Posted Date: 2012-05-11

Lead Sponsor: Pfizer

Registration Number: NCT01188759

Anidulafungin in Patients With Hematologic Malignancies

Phase 2

Terminated

Conditions: Hematologic Malignancies

Interventions: Drug: Anidulafungin

First Posted Date: 2010-01-22

Last Posted Date: 2012-03-02

Lead Sponsor: Elisabethinen Hospital

Target Recruit Count: 10

Registration Number: NCT01053884

Locations: 🇦🇹
Elisabethinen hospital, Linz, Upper Austria, Austria

Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment

Phase 2

Terminated

Conditions: Ventilator Associated Pneumonia
Respiratory Tract Infection

Interventions: Other: Normal Saline
Drug: anidulafungin

First Posted Date: 2009-07-08

Last Posted Date: 2021-02-01

Lead Sponsor: Daren K. Heyland

Target Recruit Count: 61

Registration Number: NCT00934934

Locations: 🇨🇦
Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada
🇨🇦
Hopital du Sacre-Coeur do Montreal, Montreal, Quebec, Canada
🇨🇦
Hamilton Health Sciences Centre, Hamilton, Ontario, Canada

and more 3 locations

Anidulafungin During Continuous Venovenous Hemofiltration (CVVHF)

Phase 2

Conditions: Acute Renal Failure
Infection

Interventions: Drug: Anidulafungin

First Posted Date: 2009-05-04

Last Posted Date: 2009-05-04

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 10

Registration Number: NCT00892359

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

Phase 4

Completed

Conditions: Central Nervous System Fungal Infections
Mycoses
Fungemia
Lung Diseases, Fungal

Interventions: Drug: Fluconazole
Drug: Anidulafungin

First Posted Date: 2009-02-12

Last Posted Date: 2014-12-17

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 200

Registration Number: NCT00841971

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
🇺🇸
UCLA Medical Cente, Los Angeles, California, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy